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Abstract
This paper aims at establishing a control mix of sys-
tem-technical and socio-dynamic factors for successful
innovative and industrial performance in pharmaceuti-
cal industry. The different entities and relations in
pharmaceutical innovation are described using the
double unity cell model. Management control is opera-
tionalized using the system theory of control and the
derived concepts of organizational flexibility and con-
trol capacity. The empirical study embraces structured
interviews with 22 R&D-Directors and questionnaires
sent to 38 heads of research departments of 14 phar-
maceutical companies, focusing on their views and
judgements regarding different aspects of management
control. Tentatively, it is concluded that the study
supplies confirming evidence for the thesis in socio-
dynamic literature that stimulating and rewarding
environments are needed to enhance R&D-productivity,
especially if they are embedded in a coherent pattern of
other socio-dynamic and system-technical factors.
1: Introduction
'Management of technology links engineering science
and management disciplines to address the planning
development and implementation of technological
capabilities to shape and accomplish the strategic, and
operational objectives of an organization 1371 In
technology management two formerly separated
approaches are combined, the system-technical
approach and the socio-dynamic approach [7]. Where-
as the system-technical approach mainly concentrates
on the technical, information and communication
aspects (such as phasing and structuring of research
projects, setting of targets in terms of time, money
and specifications [38, 39]), the socio-dynamic
approach [4,35] concentrates on problems of leading
and organizing people to achieve the objectives of the
organization. Repeatedly, researchers have pointed to
lack of effectiveness because social and/or human
factors have not been taken into consideration when
designing the system [7]. Especially the management
of science-based industries [30] presents its own
unique challenges. Fisscher [15] emphasises that
management control (control conducted by manage-
ment) to be effective in research organizations, sys-
tem-technical and socio-dynamic approaches should
be combined. It is the aim of this paper to establish a
control mix of system-technical and socio-dynamic
factors for successful innovative and industrial per-
formance. The views and judgements of the research
management, the heads of the research departments,
responsible for different parts of the innovative pro-
cess, are taken as the starting point for the analyses.
The basic research questions are: Can management
control positively influence the performance and
effectiveness in pharmaceutical industry? And if so,
which instruments of control should be used; for
instance, tight control, with strict planning of every
step of the research process, or loose control, leaving
space for the individual researcher? And is there a
difference in this relationship in the research and the
development phase [13]. Because pharmaceutical
industry is extremely technology driven, the pharma-
ceutical innovative process was chosen as the domain
of the study. Capron [10], comparing 135 companies
in 10 high technology industries, under which 22
branded ethical drug firms, concludes that the ethical
(prescription) drug industry attains both the highest
short-run and long-run return on R&D-investment.
In section 2 the theoretical background of the study is
discussed. In section 2.1 the different entities and
relations, are described using the double unity cell
model of pharmaceutical innovation, initially devel-
oped by van Engelen [14] for the marketing sector. In
section 2.2 the variables of management control are
defined based on the system theory of control [25].
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Exhibit 1 Double Unity Cell Model of Pharmaceutical Innovation
Section 2.3 discusses the different per formance and
effectiveness variables and section 2.4 the expected
relations between management control and perform-
ance and effectiveness. The study design is discussed
in section 3 and the results in section 4. In the final
section 5 the conclusions are discussed.
2: Theoretical background
2.1: Pharmaceutical innovation
In the context of this paper, pharmaceutical innova-
tion is defined as the whole R&D-process, starting
with the discovery of the lead compound (a chemical
compound with assumed therapeutic efficacy), and
the succeeding development process aiming to bring
this lead to the market, and the post marketing sur-
veillance activities, aiming to improve the product
(e.g. search of side effects with low and moderate
incidence, and improvements in drug delivery). In
exhibit 1 pharmaceutical innovation is presented as a
chain of double unity cells (DUC's). Each cell depicts
a clearly distinguishable phase in this process con-
cluded by a milestone (M, - M,), such as a patent at
the end of the discovery (M0) or a marketable drug at
the end of the development phase (M 2). The basic
assumption has been that the pharmaceutical innova-
tion can be viewed upon as a (chain of) value adding
learning loops [20, 33] through which research input
(I) is converted into output (0), while control over
the transformation process (T) is conducted by the
research management (R, the heads of the different
research departments). Top management includes,
the Board of Directors, assisted by the R&D Man-
agement, the (sub)-Directors of R&D (for instance,
the Directors of Discovery, Pharmaceutical Develop-
ment, and Clinical Development), and the R&D
planning departments. The Board of Directors moni-
tors the general environment [23] and sets the objec-
tives (0) which the research management has to
meet. 'Values and Visions: A Merck Century' [26] is
a good example of a long term vision on the drug
market in the decades to come. The research man-
agement monitors the task environment [13] and
renders account of the progress of the different
R&D-projects (A). In the discovery phase, monitor-
ing of the task environment includes the scanning of
the international scientific network [8] on new and
innovative ideas. The network includes, for instance,
the biomedical departments in universities, health
research institutes, biotechnological and other phar-
maceutical industries. Gambardella [17] concludes in
an extensive study of the relations between 'in-house'
scientific research and external scientific knowledge in
US pharmaceutical industry, that: 'To be part of a
network and to be to effectively exploit the information
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that circulates in the network, has become even more
valuable than being to generate new knowledge auton-
omously.' Also in the development phase monitoring
of the task environment is essential. But here the
primary goal is to broaden the contacts with phys-
icians (the clients of the companies and the conduc-
tors of the clinical trials) and with other pharmaceuti-
cal companies, in order to provide a learning curve
for eventual marketing of the new product. In order
to limit the integration problems lateral and cross-
functional communication (C) is intensified enor-
mously. Researchers of different phases of the R&D-
process, and staff members of marketing and produc-
tion discuss the ongoing research projects on a reg-
ular basis.
2.2 Management control
In management practice, control is often defined with
a narrow scope, including monitoring and correcting
(often in financial terms: budget control). However,
the systems theory of control originates from a much
broader paradigm as: 'any way of (goal)-directed influ-
ence' [25]. In this broad concept, control can be
conducted by different actors and agencies, such as
an outside agency, the management or an information
system. In this study the attention will be directed to
control exerted by the management, shortly manage-
ment control. The type and level of management
control can be considered to be a resultant of organ-
izational flexibility and control capacity [41]. Organiz-
ational flexibility refers to the ability of the organiz-
ation to adapt to changing situations, reflected, for
instance, in the level of rigidity of the administrative
rules. It ranges from operational, via structural to
strategic flexibility. Operational flexibility refers to the
ability of the organization to make routine adapta-
tions to changes in the environment; structural flexi-
bility to adaptive changes; whereas strategic flexibility
refers to non-routine proactive changes of the organ-
ization and the environment [41]. The extremes are
roughly comparable to a mechanistic versus an
organic organization [9], or a bureaucratic versus a
normative culture [19]. The control capacity refers to
the quality and competence of the research manage-
ment to achieve adaptations given the level of organ-
izational flexibility. A highly competent research
management may reach a high adaptation level, even
if the organization is relatively inflexible, whereas a
less competent research management may fail, even if
the organization as a whole is highly flexible. In this
study, 'subjective' views and judgements of the
research management (R) regarding organizational
flexibility and control capacity has been combined
with 'objective' measures regarding the innovative
process, such as the number of incentives and the
frequency of project team meetings
Management control is divided into system, process
and external control. System control refers to the
control over the personnel and material resources of
the double unity cell. It is divided into personnel and
resources control. Personnel control refers to the
'objective' quality of the reward system (organi-
zational flexibility: number of (material and imma-
terial) incentives, career policy etc.) on the one hand,
and the competence of the top management to react
on changing situations (control capacity: e.g. pace and
manner of conducting reorganizations). The challenge
of technology management is to create the conditions
conducive to meet the corporate goals of scientific
performance (system-technical performance) as well
as the scientists need for satisfaction and motivation
(socio-technical performance). Several examples of
effective reward systems for researchers have been
reported [e.g. 3, 21, 22]. They all point at the import-
ance of recognition, individual rewards, open com-
munication, self development and growth in enhanc-
ing motivation and performance of R&D personnel.
However, a study done by Gerpott [cited in 24] in
German pharmaceutical industry, pointed at the
importance of pecuniary rewards. In this study the
material and immaterial incentives mentioned by
Jauch [21] are used to operationalize the 'objective'
quality of the reward system. Resources control refers
to the level of control over the resources in the
double unity cells. It is assessed by the subjective
assessment of the adequacy of personnel and material
resources, the laboratory equipment, devices and
space. For obvious reasons the assessment of
adequacy is expected to associate with the 'objective'
size of the research budget. In addition administrative
control was assessed, the estimated pace of adminis-
trative procedures for appointment and procurement
of equipment and the reallocation of a larger part of
the personnel and material resources to a new
research field. In fact this is a reflection of the result-
ant of organizational flexibility and control capacity at
the operational level.
Process control is divided into planning and research
process communication. The assessment of the im-
portance of strategic, tactical and operational
planning by the top management on the every day
research work, relates to the goal setting-accounting
relationship between the research and the top man-
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Exhibit 2. Model of the relationships between management control and performance and effectiveness (between
brackets, reference to exhibit 1)
Management control
	
Performance and effectiveness      
System control (DUC)
Personnel control
Effectiveness
Resources control
Adequacy
Administrative control 
Industrial + innovative
Industrial + innovative
Industrial + innovative      
Process control
Planning (A,G)
Research process comm. (C)  
Innovative
Innovative      
External control
Research network comm. (RNC)  Industrial + Innovative     
unpredictable. It is therefore expected that the rela-
tively high task uncertainty [13, 17, 20] in the dis-
covery phase, connected with the unpredictability of
research activities, will be reduced by intensive con-
tacts, internally with colleagues in the discovery phase
and externally with scientists and physicians on con-
gresses. So it is expected that the frequency of
research meetings and international communication
will be dividing parameters between less than average
and more than average performers. Contrary to this,
the toxicological and clinical testing in the pharma-
cological and clinical development phases can be
planned according to strict schedules. In the relatively
certain environment of the development phase it is
expected that the level of planning and the lateral and
especially the cross-functional communication with
marketing and production will be important parame-
ters, dividing the more than average from the less
than average performers. In exhibit 2 a model is
presented of the expected relationships between the
different management control and performance and
effectiveness variables.
3: Study design
Twenty pharmaceutical companies with major
research laboratories in the EC were approached.
The companies were selected on the basis of their
(world wide and European) sales volume of branded
ethical drugs, and on their innovative capacity,
measured by the number of R&D-staff and the num-
ber of patents submitted with an European priority.
Quantitative questions, regarding output, budget and
staff were sent to the Board of Directors of the com-
panies. In addition, structured interviews were held
with the Research Directors of Discovery, Pharmaco-
logical and Clinical Development about research
management in general. To avoid misinterpretation
the structured interviews were tape recorded. The
written summaries of the interviews were sent to the
respondents for approval. Companies were
subsequently invited to participate in a more in-depth
study of the management situation. For this purpose
12-page questionnaires were sent to the Heads of the
Different Research Departments. They were asked to
give actual information about the management and
organization and to state their subjective judgements
regarding a number of managerial and organizational
aspects. For most of the items Likert's 5-point
response format was used; a limited number of items
was assessed with 2 and 3-point response formats. In
order to assure an uniform interpretation, definitions
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agement (0 and A in exhibit 1). Research process
communication on the contrary, relates to control
capacity at the research management level, the grad-
ual transition from 'hands on' to 'hands off control
(relatively close to relatively loose monitoring by the
research management). It is divided in the frequency
of research (project team) meetings and in-house
communication, and the attendancy mix. The atten-
dancy mix refers to lateral and cross-functional com-
munication: are only researchers of the own double
unity cell attending the meetings, or also researchers
from other R&D-phases and/or marketing and pro-
duction present (the communication relationships C
in exhibit 1). External control refers to the communi-
cation with the R&D-environment and is assessed by
international communication. International communi-
cation is measured by the frequency of international
contacts with scientists, physicians and colleagues of
other companies, for instance on scientific congresses
and workshops.
23: Performance and effectiveness
Whereas performance is related to absolute output,
effectiveness relates output to invested input [2].
Performance and effectiveness are multi-dimensional
concepts. They can be measured at different organiz-
ational levels and at different points in the primary
and secondary processes of the organization. In this
study the performance and effectiveness is measured
at the level of the research process (innovative per-
formance and effectiveness, the milestones M, and
M, in exhibit 1), and at the level of the company as a
whole (industrial performance and effectiveness).
Whereas innovative performance and effectiveness
primarily relates to the control capacity of the
research management, industrial performance and
effectiveness is primarily related to the top manage-
ment level and thus to organizational flexibility.
To assess innovative performance and effectiveness
two measures are used in this study. The number of
patents is used as a measure for performance and
effectiveness in the discovery phase. The length of the
developmental process is considered to be one of the
most important performance measures influencing
the profitability of a pharmaceutical company [34, 36,
43] and is therefore used as a measure for effective-
ness in the development phase. High barriers for new
entrance [33] are raised by a constant stream of new
drugs, by improvement of existing drugs, and by their
use for an expanded range of indications [36].
Because drugs are often relatively easy to imitate by
competitors, patents are a highly significant form of
resources control, and thus a very important source
of market power for the companies holding them.
For this reason, the number of patents is an import-
ant measure for R&D effectiveness in the discovery
phase. However, there are a number of problems
involved in the use of patent statistics, for instance
the possible difference in patenting policy (timing and
scope) between companies [6, 31], the difference
between leading (real innovative), defensive and
follow on (me-too) patenting, as well as the increased
importance of in- and outlicencing in order to attain
a complete patent portfolio [16, 17, 40]. In a previous
papers of the authors these problems are discussed in
more detail [28].
Innovation, although essential, is not enough to reach
the goal of attaining long term profitability for the
company. It is obvious that without an adequate mar-
keting and sales structure an innovative drug would
never reach its full profit potential. Vos [42] analyzed
two companies, which in a joint venture developed a
new drug. The succeeding marketing effort, however,
was done separately. The firm with the best R&D-
marketing interface clearly got the highest short and
long term return on investment. Therefore, the indus-
trial indicators, the annual growth rate and the oper-
ating profit margin are used as independent variables
in the present study.
2.4: Expected associations
The variables of system control are more directly
related to the objectives and tasks of the top manage-
ment, and thus to organizational flexibility than to the
control capacity of the research management. It is
therefore expected that these variables will be primar-
ily associated with the industrial performance and
effectiveness variables, which reflect the performance
of the organization as a whole. Most variables of pro-
cess and external control on the contrary, primarily
reflect the control capacity of the research manage-
ment. They are therefore expected to be primarily
associated with innovative performance and effective-
ness.
The research conducted in the different phases of the
R&D-process varies considerably. In the discovery
phase the screening and testing for the identification
of a promising lead compound is conducted.
Although the use of new techniques has made the se-
arching for the lead compound less fortuitous, the
research work in the discovery phase is still highly
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of the variables were included in the questionnaires.
Before the data collection started the questionnaires
were tested on three staff members of pharmaceutical
and chemical industry. Their comments were incor-
porated into the questionnaires.
Different statistical methods are used to analyze the
data. In general, substantive conclusions are suppor-
ted by all statistical techniques. For the clarity of
presentation the bivariate relationships are presented
using Oneway Anova. Non-parametric analysis of
group means, using the Kruskal Wallis test, does not
alter the conclusions. Cronbach's a [12] was calcu-
lated to check for the internal consistency of the sub-
scales, supposed to measure a single concept.
4: Results
4.1: Data collection and reliability
Fourteen companies agreed to participate, (a
response rate of 70%). Twenty-two structured inter-
views were held with the Directors of Discovery, and
Pharmacological and Clinical Development (1 to 2
interviews per company). In addition, 10 companies
agreed that questionnaires about personnel, budget
and research policy, would be submitted to the heads
of the different research departments. In total 59
questionnaires were sent, of which 38 were returned
(3 to 4 questionnaires per company laboratory, an
individual response rate of 64%). In order to investi-
gate in how far the companies in this study can be
regarded as being representative for the population of
large pharmaceutical innovative companies, the size
and the innovative capacity was measured. Nine of
the companies are among the top 20 companies
ranked according to the world wide ethical drug sales
in 1991. The other five are top 50 pharmaceutical
companies. Patent analysis revealed that from 1985 to
1991 in total 3,874 licensees submitted pharmaceutical
patents to the European authorities. The actual num-
ber of licensees will be less, because especially con-
glomerates use different licensee names and
addresses. A rough estimation based on the com-
panies in this study would suggest that about 2,500
different companies submitted patents in this period.
The strong innovative capacity of the companies in
the study sample was indicated by the fact that 25%
of all these patents were submitted by the companies
in this study.
4.2: Study base description
Exhibit 3. Descriptive statistics of size, performance
and effectiveness measures (N=14).
Mean (s.d.)
Size
Sales ($m) 3,372 (1,913)
R&D-expenditures ($m) 540 (248)
Discovery ($m) 126 (70)
Development ($m) 390 (209)
Performance and effectiveness
Number of patents 73 (62)
Patents / $10m 5.3 (2.6)
Length of development (years) 9.3 (2.1)
Annual growth rate (%) 10.5 (4.5)
Operating profit margin (%) 23.6 (11.2)
Exhibit 3 shows that the companies in the study grew
vigorously from 1986 to 1991, with about 10% a year.
The average sales volume of branded ethical drugs
amounted $3,4 billion, with a operating profit margin
of 24%. As could be expected of a science-based
industry, the average R&D-expenditures are high,
about 15% of the total sales volume of ethical drugs.
About 25% of the total R&D-expenditures was spent
on discovery, which resulted in about five patents per
$10 million per year. The development phase has a
long duration, it took the companies in the sample on
average more than 9 years to finish the pharmacologi-
cal and clinical testing, necessary to bring a lead
compound to the prescription drug market.
Exhibit 4 shows that the volume of the world wide
sales of branded ethical drugs is highly correlated
with a number of the performance and effectiveness
variables. The correlation with the R&D-expenditures
and the length of the development phase are not
astonishing. There is a budget relationship between
the sales volume and the R&D-expenditures, and a
larger R&D-effort can be translated into a shorter
length of the developmental process. More interesting
is the positive correlation with the number of patents
per R&D-investment in discovery and the operating
profit margin. Part of the first correlation might
reflect a more aggressive patenting policy. The larger
companies can probably afford to spend the high
costs for patenting (especially patent fees and transla-
tion costs) more easily than the medium-sized com-
panies. The positive correlation of world wide sales
with the operating profit margin would suggest that
larger companies are more successful. This would
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Exhibit 4. Pearson product-moment correlations of size and performance (N=14).
The R&D-expenditures, spent on development, are significantly correlated with annual growth rate (.58')
p < .1; p < .05;	 p < .01, 2-tailed significance
provide supportive evidence for the recent concentra-
tion tendencies in pharmaceutical industry. In a
recent article of the authors the possible occurrence
of economies of scale in pharmaceutical innovation is
discussed more thoroughly [29]. Also R&D-expendi-
tures, development length and patents per R&D-
investments are all correlated with size.
Exhibit 5. Descriptive statistics {mean and (s.d.)}
and Cronbach's a (+ number of items) of manage-
ment control variables (N=38).
Mean Cronbach's a
Personnel control
Effectiveness 3.33 (1.02) .85 (12)
Resources control
Adequacy 3.56 (.63) .90 (4)
Administrative control 3.48 (1.26) .78 (4)
Process control
Planning 3.78 (1.57) .79 (6)
Frequency 3.07 (.88) * (1)
Attendancy mix 2.37 (.51) .72 (5)
External control
Int. communication 3.46 (1.31) * (1)
Exhibit 5 shows that in all cases Cronbach's a is suffi-
ciently high (> .72) to warrant confidence in the
internal consistency of the scales. It also shows that
the average assessment of the management control
situation is rather positive. The assessment of the
effectiveness of personnel policy, the adequacy of the
research budget, laboratory equipment and devices,
as well as the pace of administrative procedures is
assessed above 3 on the likert 5-point scales. The
assessment is especially more positive if it is com-
pared to research institutes and academia. In a com-
parative study, the average assessment of professors
and senior scientific staff in 57 Dutch biomedical and
pharmaceutical research departments the average
assessment was one half to more than one point
lower. Especially in academia the average assessment
was rather negative [27].
Exhibit 6 shows the first-order comparisons of the
different performance and effectiveness measures
with size and management control. The mean values
are presented for high and low performers. A median
split was made, based on the answers to question-
naires to the heads of the different research depart-
ments. In most cases a clear division could be made
at the median level. Only in the case of the operating
profit margin a clear division was found at another
level. In six companies the operating profit margin
was below 17%, and in the other eight companies it
was above 28%. Because no companies showed
scores between 17% and 28%, the division was
placed at this level. The relationships of size and the
different performance and effectiveness variables as
discussed in exhibit 4, are evident again, with addi-
tional information about the group means. More
interesting is the observation that the effectiveness of
personnel policy turns out to be significant for three
of the four performance measures. For all four per-
formance measures holds that the assessment is clear-
ly negative (below three on the Likert's 5-point scale)
in the low performing companies, and clearly positive
in the high performing companies. However, because
of the inter-correlation of size and the effectiveness
of personnel policy, only the multivariate analysis can
indicate whether or not the effectiveness of personnel
policy has additional explaining value. A short devel-
opment phase is also significantly associated with the
adequacy of resources, the importance of short term,
middle term and long term planning and the atten-
dancy mix, indicating a higher level of lateral and
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from the average performers [27]. Possibly, the oper-
ating profit margin not only provides the best reflec-
tion of the quality of the mission of pharmaceutical
industry, but also for the sector of R&D. This is in
accordance with the conclusion of van Engelen [14]
for the marketing sector. It can be argued, however,
that the causality may be opposite to the direction we
suggest for. The more effective companies are also
the most profit and can therefore afford to spend
more on elaborate laboratory equipment, have more
frequent international contacts and can have quicker
procurement and appointment procedures. Also the
R&D staff in the better companies is likely to
respond more positively than their colleagues in the
less performing ones. However, because of the size of
the companies it may be expected that spending
budgets will not be so much of a bottleneck for pro-
curement, appointment and international travelling.
Also the consistency of the results presented in this
paper with previous studies [e.g. 1, 8, 32, 39, 41] leads
us to prefer our interpretation.
Personnel control turns out to be the most important
socio-dynamic factor dividing the more than average
from the less than average performers. No matter
which measure of performance and effectiveness is
taken, the perceived effectiveness of personnel policy
comes out as the most important management con-
trol variable. This can be considered as a clear confir-
mation for the thesis in socio-dynamic literature, that
stimulating and rewarding environments which
enhance the motivation of the R&D-personnel, are
needed to encourage innovation [4, 11, 21, 22].
The predicted differences between research and
development are recovered in the results. In the
structured interviews it became apparent, that the
best performing pharmaceutical companies more and
more shift their attention from the screening of thou-
sands of chemical compounds in pharmacological and
animal models, to the understanding of the biochemi-
cal and physiological background of diseases. The
screening process itself is becoming increasingly
automatized. Exhibit 6 shows that in the most effec-
tive discovery departments in terms of number of
patents, the frequency of project team communication
is significantly higher than in the average performers.
The significant correlation of the industrial perform-
ance and effectiveness variable annual growth rate
with th attendancy mix, however, was not expected.
This high correlation probably originated from the
association of this performance variable with the
R&D-expenditures, spent on development (see
exhibit 4). Apparently the recent strategy to concen-
trate on development, in order to introduce drugs
with small improvements on a regular basis [36],
becomes more and more rewarding.
Considering the limited patent protection time, shor-
tening the length of the developmental process is
essential for attaining profitability in a pharmaceutical
company. As one of the Research Directors put it:
'Each day a successful drug reaches the market earlier
earns $200.000 for the company'. With this figure in
mind, it is obvious how large the benefits can be for
companies, which are able to shorten the develop-
mental process. In the relatively certain situation of
the development phase a positive correlation is found
of shorter development length with the assessed
importance of strategic, tactical and operational
planning by the top management, and the attendancy
mix, indicating the essential role of lateral and cross-
functional communication in technology management.
Researchers of different phases of the R&D-process
in high performing companies stood in very close
contact with each other and with marketing and
production, in such a way that an optimal monitoring
of the process could be reached. Interestingly, the
close monitoring of the developmental process did
not go hand in hand with a high frequency of project
team meetings. Most of the pharmaceutical com-
panies in this study are multinationals with labora-
tories in different countries. A high frequency of
meetings in development phase would mean a lot of
travelling. Mutual adjustment was therefore attained
mainly by telecommunication. In cases of very fre-
quent project team meetings, even a tendency
towards ineffectiveness was observed.
It should be considered that the analyses presented in
this paper are far from decisive, because of the rela-
tively small study population and the use of a cross
sectional design. Therefore, the following control mix
for effective pharmaceutical innovation can only be
formulated tentatively: 1. much attention is paid to
human resources management; 2. the administrative
procedures are carried out quickly; 3. there is a flexi-
ble adjustment to changing situations; 4. much atten-
tion is paid to the building and maintaining of an (in-
ternational) R&D-network; 5. the research process in
the discovery phase is characterised by intensive 'in
house' communication; 6. in the development phase
much attention is paid to planning and lateral and
cross-functional communication.
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Exhibit 6. Comparison of size and management control on different performance measures. Group means of
high and low performers and F-values
Patents/R&D-exp.
low	 high
F-value Devel. length
long	 short
F-value
Size
Sales ($billion) 2.2 3.8 3.82' 2.2 4.5 7.53-
R&D-expenditures 342 537 3.4.8' 315 653 10.92.-
Personnel control
Effectiveness 2.50 3.93 4.98' 2.13 3.13 5.01'
Resources control
Adequacy 2.33 3.30 2.30 2.60 4.05 4.43'
Administrative control 3.40 2.91 .40 2.33 3.59 2.48
Process control
Planning 3.45 4.60 2.58 3.25 4.75 4.76'
Frequency 3.85 4.37 3.52' 4.18 4.07 .09
Attendancy mix 4.33 4.50 .08 2.12 3.28 5.56-
External control
International communication 3.85 4.00 .05 3.85 4.00 .04
Profit margin F-value Growth rate F-value
low high low high
Size
Sales ($billion) 2.4 4.1 3.45 2.6 3.6 .94
R&D-expenditures 377 570 2.33 361 553 2.27
Personnel control
Effectiveness 2.33 3.87 6.13 2.67 3.56 1.53
Resources control
Adequacy 3.22 3.62 .36 3.43 3.46 .28
Administratieve control 2.42 3.67 1.90 2.87 3.56 .68
Process control
Planning 3.70 3.82 .02 4.06 3.80 .09
Frequency 3.06 3.08 .00 3.80 4.38 3.52'
Attendancy mix 2.34 2.37 .01 2.32 3.27 3.10
External control
International communication 3.08 4.06 6.98' 3.80 4.06 .13
cross-functional communication. The frequency of the
project team meetings turns out to be significantly
higher in the case of high performance in the dis-
covery phase and for growth rate. Finally, the operat-
ing profit margin is also significantly associated with
international communication.
5: Discussion and conclusions
One of the most striking results is that the best per-
forming companies in terms of innovative and indus-
trial capacity clearly differ from their less performing
competitors on a number of socio-dynamic and sys-
tem-technical features, regarding both organizational
flexibility and control capacity. In the companies with
the largest operating profit margin the perceived
effectiveness of personnel policy (a socio-dynamic
factor regarding organizational flexibility) is better
than in the average companies. The average duration
of the administrative procedures is clearly shorter (a
system-technical factor regarding organizational flexi-
bility), and the international communication with
scientists, physicians and colleagues on congresses
and workshops is more intense {a socio-dynamic
factor combining elements of organizational flexibility
(e.g. available travelling budget) and the control
capacity of the research management). Interestingly,
also in universities and institutes personnel, adminis-
trative and external control separate the outstanding
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Appendix 1. Operationalization of the measurements of manage-
ment controL
System control
Personnel control
Effectiveness
Subjective assessment of the effectiveness of personnel policy {3
and 5-point response formats, higher values indicate a more
positive assessment, for instance: How much emphasis is laid on
career planning in your organization? No emphasis at all (1-2-3 .4-
5) Very much emphasis} regarding:
- Pace and manner in which reorganizations are executed.
- Cases concerning appointment, promotion and dismissal.
Material incentives:
- Primary and secondary working conditions, for instance average
salary level in comparison to management functions and com-
petitors.
- Stocks, options and use of company car etc.
- Extra payment for extraordinary research efforts.
Immaterial incentives:
- Career planning and training facilities.
- Good reputation of the organization.
- Career possibilities within the organization or as a step-up
towards other organizations.
- Recognition, eg. possibilities for scientific publishing and presen-
tation, or a dual ladder system and fellowships.
Resources control
Adequacy
Subjective assessment of the adequacy {5-point response formats,
for instance: How long would it take to reallocate a larger part
(e.g. 20%) of the personnel and material means to a new field of
research? (1) (less than) one month; (2) 1 to 3 months; (3) 3 to 6
months; (4) 6 to 12 months; (5) (more than) a year) of:
- Personnel and material resources.
- Advanced laboratory equipment, devices and space.
Administrative control
Subjective assessment of the speed of the administrative pro-
cedures (5-point response formats, 1 = (more than) a year, 5 =
(less than) a month}:
- Appointment and procurement of equipment (USS 50,000).
- Reallocation of a larger part (20%) of the personnel and
material resources to a new research field or therapeutic area.
Process control
Planning
Subjective assessment of the importance of short and middle
range planning by higher management on the every day research
work {5-point response formats, for instance: the annual research
plan drawn up by the laboratory directorate serves as an import-
ant guideline for the planning and monitoring of the research
group program. Disagree entirely (1-2-3-4-5) Agree entirely).
Frequency
Frequency of research meetings {5-point response format: 1 =
(less than) once in six months; 5 = (more than) once a week).
Attendancy mix
General attendancy of research meetings: only researchers of the
own R&D-phase or also staff members of other R&D-phases
and/or marketing and production (5-point response formats,
higher values indicate a higher level of lateral and cross-functional
communication).
External control
International communication
Frequency of international contacts with scientists and physicians
and colleagues of other companies, for instance on congresses and
workshops {5-point response format, 1 = (less than) once a year;
5 = (more than) once a month).
Appendix 2. Operationalization of the measurements of size,
performance and effectiveness.
Size
Sales volume
World wide sales of branded ethical drugs in 1991 in USS million.
R&D-expenditures
R&D-expenditures in 1991 in USS million. The total expenditures
and the separate expenditures for drug discovery, pharmacological
and clinical development, and post marketing surveillance.
R&D-performance and effectiveness
Number of patents per R&D-investment
The average annual number of patents for New Chemical Com-
pounds, submitted world wide with first priority date from 1985
till 1991 (Pharmdoc Section of the World Patents Index Database
of DERWENT Publications, process and formulation patents have
not been considered) per USS 10 million R&D-expenditures in
discovery.
Length of development
The average time span between patenting of the lead compound
and the launch of the registered drug on the prescription drug
market (years .[ ). Estimation of the Research Directors of the time
span between patenting and launch of anti-hypertensive and anti-
ulcer drugs. These drugs were chosen because the development-
process is neither relatively short (antibiotics) nor very long (anti-
psychotics). In five companies the reported length was checked for
ten drugs which were launched after 1987. In all cases the findings
proved to concord.
Industrial performance and effectiveness
Operating profit margin
Operating result/revenues. Operating result = result after deduc-
tion of normal operating charges and before financial income and
expenses, taxes etc. Revenues = net turnover including other
operating revenues, change in stocks and capitalized costs.
Annual growth rate
The average annual growth rate of the company from 1985 till
1991, both organic growth and growth through acquisition.
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